ecancermedicalscience

Research

PD-1 or PD-L1 inhibitors in addition to first-line chemotherapy for endometrial cancer: an extracted individual patient data meta-analysis

1 Apr 2025
Mariana Carvalho Gouveia, Renata Colombo Bonadio, Felippe Lazar Neto, Maísa Maria Spagnol Trento, Mateus Trinconi Cunha, Mariana Scaranti

Objective: To assess the impact of PD-1/PD-L1 inhibitors in first-line treatment of advanced or recurrent endometrial cancer (EC) through individual patient data (IPD) Meta-analysis, providing insights by integrated survival curves.

Methods: We searched PubMed, Embase, Cochrane and meetings up to April 2024 for randomised phase II or III trials (randomised controlled trials) investigating immunotherapy plus chemotherapy for EC. IPD was reconstructed from Kaplan–Meier plots using WebPlotDigitizer and the R package IPDfromKM, and then combined.

Results: NRG-GY018, RUBY, MITO END-3, AtTEnd/ENGOT-en7 and DUO-E were included. 2,436 patients were analysed for progression-free survival (PFS) and 2,317 for overall survival (OS). Among these, 621 patients had deficient DNA mismatch repair (dMMR) and 1,815 had the proficient disease (pMMR).

The IPD analysis highlighted the significant benefit of adding immunotherapy to chemotherapy in dMMR patients, with 3-year absolute gains of 36% in PFS (HR 0.36, 95% CI 0.28–0.45) and 28% in OS (HR 0.41, 95% CI 0.30–0.48).

For pMMR, a smaller benefit was observed in PFS, with a 3-year absolute gain of 6% (HR 0.78, 95% CI 0.69–0.88). Notably, a significant benefit occurred only with PD-1 inhibitors (PFS HR 0.66, 95% CI 0.55–0.79; OS: HR 0.78, 95% CI 0.62–0.96). No significant benefit was seen with PD-L1 inhibitors (PFS: 0.87, 95% CI 0.75–1.03; OS: HR: 0.93, 95% CI 0.75−1.16).

Conclusion: This meta-analysis validated the benefit of adding immunotherapy to platinum-based chemotherapy with respect to PFS. dMMR patients gain advantages from the inclusion of either anti-PD-1 or anti-PD-L1 agents, whereas pMMR patients only experience this benefit when treated with anti-PD-1 agents.

Related Articles

Anass Baladi, Hassan Abdelilah Tafenzi, Fatim-Zahra Megzar, Ibrahima Kalil Cisse, Othmane Zouiten, Leila Afani, Ismail Essaadi, Mohammed El Fadli, Rhizlane Belbaraka
Shreekant Dadheech, Kaustubh Burde, Pariseema Dave, Ruchi Arora, Chetna Parekh
Kofi Effah, Ethel Tekpor, Comfort Mawusi Wormenor, Joseph Emmanuel Amuah, Vida Kwawukume, Louisa Ademki Matey, Seyram Kemawor, Stephen Danyo, Esu Aku Catherine Morkli, Nana Owusu Mensah Essel, Emmanuel Timmy Donkoh, Patrick Kafui Akakpo
Arunah Chandran, Ishu Kataria, Kunal Oswal, Rita Isaac, Meritxell Mallafré-Larrosa, Sathishrajaa Palaniraja, Rajaraman Swaminathan, Rohit Rebello, Nandimandalam Venkata Vani, Bindhya Vijayan, Moni Kuriakose, Arnie Purushotham, Rengaswamy Sankaranarayanan, Jerard Selvam, Richard Sullivan, Partha Basu